Objective - To describe the health status of insulin-dependent type 2 diabetics (T2D-ID) and their care. Patients and methods - For the Entred 2007 study, a random sample selected 8,926 adults with diabetes who had been reimbursed for at least three antidiabetic medications over the past 12 months. Medical records were available for all participants; patient questionnaires were available for 48% and physician questionnaires for 28%; 92% (n = 3,894) had T2D, of whom 18% (n = 716) were treated with insulin. Results - T2D patients with insulin resistance (T2D-IR) were on average slightly older than T2D patients treated with oral antidiabetic drugs (OADs) alone (68 vs. 66 years), but more importantly, they had had diabetes for a longer duration (17 vs. 10 years, p < 0.0001) and were diagnosed at a younger age (51 vs. 55 years, p < 0.0001). Insulin therapy was associated with a higher prevalence of obesity (43% vs. 39%, p = 0.03), a higher frequency of HbA1c > 8% (35% vs. 11%, p < 0.0001), and more frequent complications, including angina or myocardial infarction (27% vs. 15%, p < 0.0001), stroke (8% vs. 4%, p = 0.01), laser eye treatment (31% vs. 14%, p < 0.0001), and plantar perforating ulcers (18% vs. 8%, p < 0.0001). Patients with T2DM were more likely to receive cardiovascular treatment (88% vs. 76%, p < 0.0001) and were more likely to undergo 3 HbA1c tests (52% vs. 42%, p < 0.0001), to consult a private cardiologist (46% vs. 38%, p < 0.0004), and a private practice endocrinologist (22% vs. 7%, p < 0.0001), as well as an albuminuria or proteinuria test (34% vs. 26%, p < 0.0001) during the year. Conclusion - Compared to T2D patients on oral antidiabetic drugs (OADs) alone, the T2D-IR population is older, has had diabetes longer, and is diagnosed at a younger age, with an extremely high prevalence of obesity: insulin therapy is therefore associated with more severe diabetes. Despite relatively closer monitoring, diabetes is less well-controlled and the frequency of complications is higher than in T2D patients treated with ADO alone. Poster cited in the journal Diabetes & Metabolism, volume 39, supplement 1.